Metraipolis › archive › dc_2d4ae4a354fa

The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review — Europe PMC PMID:41822624

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41822624
DOI
10.7759/cureus.103234
License (as archived)
solo-consultazione
Archived
2026-11-06T01:03:43.869Z
SHA-256 of the archived text
055832879feede661ac7a4dc00ccc917f1398ccfc2bf834be50c6efd5e5c8d41
Stable URL of this page
https://metraipolis.com/documento/dc_2d4ae4a354fa

How to cite

The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review — Europe PMC PMID:41822624 — Europe PMC (en), https://europepmc.org/article/MED/41822624 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2d4ae4a354fa (Metraipolis archive dc_2d4ae4a354fa, sha256 055832879feede661ac7a4dc00ccc917f1398ccfc2bf834be50c6efd5e5c8d41)
BibTeX
@misc{dc2d4ae4a354fa,
  title = {The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review — Europe PMC PMID:41822624},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41822624},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2d4ae4a354fa; sha256 055832879feede661ac7a4dc00ccc917f1398ccfc2bf834be50c6efd5e5c8d41},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41822624. Agents can read the archived copy with the MCP tool read_document.